COEPW   $0.0818  5.42% Market Closed

Coeptis Therapeutics Holdings Inc
Last Events:

2023-07-18 Trend pattern changed from восходящий треугольник to нисходящий треугольник.

2023-07-18 Signal in Stochastic changed from bearish to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-07-18 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.

2023-07-18 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-07-18 Signal in EMA100 changed from bullish reversal to bearish reversal. 2023-05-22 the price crossed down the moving average line and formed a short-term downside trend.

2023-07-18 Signal in EMA20 changed from bullish reversal to bearish reversal. 2023-05-22 the price crossed down the moving average line and demonstrates a downside trend.

2023-07-18 Trend Power changed from slow to almost flat.

2023-05-22 Signal in Stochastic changed from bearish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: signal line crossed the middle level.


Current temperature: 0.00
ST: 0, Cor:

Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total - Buy -
rsi Sell - -
macd - - -
stoch - - -
ma20 ActivelyBuy - -
ma50 - - -
ma100 - Buy -
ISIN US19207A1161
ceo Mr. David Mehalick
Website https://coeptistx.com
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.